Three Republican State AGs File Suit Over Cannabis Reform

Three Republican attorneys general have filed a marijuana rescheduling lawsuit against the Trump administration, calling the federal cannabis reform unlawful and demanding its reversal. Indiana, Nebraska and Louisiana brought the challenge to the United States Court of Appeals for the District of Columbia Circuit. Their petition argues the action “fails to comport with the requirements” of federal law, was “improperly promulgated,” and is “arbitrary, capricious, an abuse of discretion.” The court should declare it unlawful and vacate it entirely, the filing states.

What Triggered the Cannabis Rescheduling Challenge?

Acting Attorney General Todd Blanche sparked the cannabis rescheduling challenge in April 2026. He directed that marijuana products operating under a state medical cannabis licence move immediately from Schedule I to Schedule III of the Controlled Substances Act (CSA). FDA-approved marijuana products would follow the same path. A separate administrative hearing in June will examine broader federal rescheduling, potentially covering adult-use products too.

The court has now consolidated the three-state marijuana rescheduling lawsuit with an earlier petition from Smart Approaches to Marijuana (SAM) and the National Drug and Alcohol Screening Association (NDASA). SAM and NDASA submitted their filing in early May. They claim both organisations suffered harm from the federal cannabis reform.

SAM chief executive Kevin Sabet welcomed the legal solidarity. “Our coalition is growing as leaders around the country recognise that this unprecedented order will cause significant harm to public health and safety,” he said. “We will not rest until this dangerous action is reversed.”

High-Profile Legal Muscle Behind the Opposition

Attorneys at Torridon Law PLLC signed the SAM and NDASA petition. Former US Attorney General William Barr, who led the DOJ during Trump’s first term, is a partner at that firm. SAM retained Barr’s firm in January 2026, shortly after President Trump signed an executive order telling officials to push the rescheduling process forward without delay.

The SAM and NDASA brief contends the cannabis rescheduling challenge rests on solid statutory ground. It argues the action “violates the rulemaking requirements of the Administrative Procedure Act” and “exceeds the statutory authority of the Attorney General under the CSA.” The defendants named across both consolidated suits include the DOJ, the Drug Enforcement Administration (DEA), Acting Attorney General Blanche and DEA Administrator Terrance Cole.

Congress Pushes Back Too

The marijuana rescheduling lawsuit is not the only pressure bearing down on the administration’s reform effort. A House committee voted in early May to block federal officials from advancing the rescheduling process further, even as the DOJ pressed ahead.

On 22 May, a federal judge dismissed a separate SAM case. That suit targeted a new Trump administration programme offering eligible Medicare patients up to $500 a year toward hemp-derived products.

A Public Health Debate With High Stakes

This widening cannabis rescheduling challenge cuts to the heart of a national disagreement over drug policy and public health. Critics of rescheduling argue that easing federal controls sends a permissive signal about marijuana’s risks, particularly to young people. Research backs up those concerns. The 2022 National Survey on Drug Use and Health found that 17.7% of Americans aged 12 or older reported using cannabis that year. That figure rises sharply among 18 to 25-year-olds, where past-month use reached 35.4%.

Federal policy shifts of this magnitude shape how communities, schools and families talk about drug use. The outcome of the consolidated marijuana rescheduling lawsuit will carry consequences well beyond the courtroom.

Source: dbrecoveryresources